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ABSTRACT Proximal subungual onychomycosis (PSO) is a rare subtype 
of onychomycosis with a clinical presentation characterized by proximal 
leukonychia in the lunular area of the nail. PSO is associated with immuno-
suppression and regarded a sign of Human immunodeficiency Virus (HiV) 
infection when caused by Trichophyton (T.) rubrum. We present two cases of 
PSO caused by T. rubrum developed during treatment with tNF-α inhibitors 
combined with methotrexate (MtX). 
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INTRODUCTION
Proximal subungual onychomycosis (PSO) is a rare 
subtype of onychomycosis found in 0.3% of cases (1). 
its clinical presentation is characterized by proximal 
leukonychia in the lunular area (2). PSO is associated 
with immunosuppression and regarded as a sign of 
Human immunodeficiency Virus (HiV) infection when 
caused by Trichophyton (T.) rubrum (1). PSO caused 
by T. rubrum has previously only been reported in a 
single patient treated with tumor necrosis factor-al-
pha (tNF-α) inhibitors and in no patients treated with 
methotrexate (3). We present two cases of PSO caused 
by T. rubrum developed during treatment with tNF-α 
inhibitors combined with methotrexate (MtX).
PATIENTS
Case 1
A 78-year-old man treated for psoriasis and psori-
atic arthritis noted a toenail change during combina-
tion treatment with etanercept 50 mg/week and MtX 
10 mg/week. Figure 1 displays a timeline of his medi-
cation. Medical history included mild nephropathy 
and a negative HiV test. 
Physical examination revealed proximal white nail 
changes on the left hallux, discrete scaling of planta 
pedis, and maceration of the lateral interdigital toe 
web. Direct microscopy of nail material displayed 
septate hyphae and a few arthroconidia. Culture and 
PCR confirmed T. rubrum infection. 
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the patient was treated for three months with oral 
terbinafine 250 mg/day in combination with daily ap-
plication of topical ciclopirox nail lacquer. Clinical im-
provement was noted at four month follow-up with 
the nail at the proximal nail fold appearing normal. 
Direct microscopy displayed a few hyphae com-
bined with a negative culture, indicating non-vital 
fungi. Mycological cure was observed eight months 
after treatment initiation and clinical cure after thir-
teen months. Figure 2 illustrates the patient’s clinical 
course. 
Case 2
A 55-year-old man with psoriatic and psoriasis ar-
thritis was referred to the Dermatologic Outpatient 
Clinic with a facial rash potentially due to infliximab. 
Medical history included inflammatory bowel disease. 
the patient had received infliximab for eight months 
and MtX for fourteen months at the time of referral. 
tinea barbae caused by T. rubrum was diagnosed and 
treated with topical terbinafine. During clinical ex-
amination a whitening of the nails the on left 1st and 
3rd toe and right 2nd toe was noted, but interpreted as 
psoriasis nails. 
At three month follow-up, tinea barbae had clini-
cally cleared, however progression of the proximal 
white nail changes was noted on the left hallux. A der-
matophyte-specific PCR from the toenail confirmed T. 
rubrum infection. HiV test was negative. treatment 
with terbinafine 250 mg/day for three months com-
bined with topical amorolfine applied once a week 
was initiated.
DISCUSSION
these two cases represent the rare manifestation 
of PSO caused by T. rubrum in HiV-negative patients 
treated with tNF-α inhibitors in combination with 
MtX. Patients with psoriasis have an increased sus-
ceptibility to dermatophyte infections (4). A study on 
onychomycosis in 315 patients with psoriasis treated 
with tNF-α inhibitors (infliximab, etanercept, and 
adalimumab) found a prevalence of 13-33% com-
pared with 14% in patients with psoriasis not treated 
with biologics. None of these patients presented with 
PSO (4). 
tNF-α inhibitors may reduce the inflammatory 
response to fungal infection. the cytokine is mainly 
secreted by macrophages and prevents the actions of 
iL-12 and interferon-γ and the migration of dendritic 
cells (5). tNF-α inhibitors mainly suppress monocytes 
and dendritic cells, while MtX inhibits activation and 
Figure 1. Patient 1: timeline of psoriasis medication and 
onset of proximal subungual onychomycosis. *tNF-α inhibi-
tors
Figure 2. Clinical course of the patient 1: A) Presentation. B) three months after treatment. C) Nine months after treatment.
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proliferation of lymphocytes (6). the combination of 
tNF-α inhibitors with MtX may further suppress the 
immune response by targeting different immune 
cells.
CONCLUSION
this is the first time PSO caused by T. rubrum has 
described in patients receiving tNF-α inhibitors com-
bined with MtX, a frequent treatment strategy. this 
condition may therefore be under-diagnosed. We 
suggest screening for onychomycosis before treat-
ment initiation and clinical follow-up during combi-
nation treatment with tNF-α inhibitors and MtX.
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